ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML
A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.
Related Articles
Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC
Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.
FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC
The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.
Tambiciclib Generates Potential OS Benefit in R/R AML
Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.
FDA Approval Is Sought for Ziftomenib in NMP1-Mutant R/R AML
The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.
The OncFive: Top Oncology Articles for the Week of 4/20
Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.
Advancing Brain Metastases Research and Mentorship in Breast Oncology: With D. Ross Camidge, MD, PhD; Nancy U. Lin, MD
Drs Camidge and Lin discussed Dr Lin’s work with brain metastases and her role in developing targeted therapies for breast cancer.
Dr Boffa on Factors Informing Early-Stage Esophageal Cancer Management
Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.
Dr Heymach on the Efficacy of Zongertinib in Previously Treated HER2-Mutant NSCLC
John V. Heymach, MD, PhD, discusses the activity of zongertinib in patients with previously treated advanced HER2-mutant NSCLC.
How Mirvetuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer
Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable…